Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$1.38 -0.7%	$1.81	$1.37 ▼ $28.65	$10.66M	5.42	39,165 shs	60,189 shs
MBIO Mustang Bio	$1.55 +1.0%	$1.76	$0.89 ▼ $21.95	$11.08M	2.22	159,560 shs	55,503 shs
PHIO Phio Pharmaceuticals	$1.98 -2.5%	$2.31	$0.97 ▼ $9.79	$11.62M	0.86	152,785 shs	75,498 shs
RDHL Redhill Biopharma	$1.34 +0.8%	$1.69	$1.06 ▼ $12.50	$3.05M	4.18	121,416 shs	18,413 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-6.71%	-10.32%	-27.23%	-59.53%	-94.83%
MBIO Mustang Bio	+1.32%	-7.27%	-19.47%	+14.18%	-89.92%
PHIO Phio Pharmaceuticals	-0.49%	0.00%	-19.76%	-0.49%	-36.16%
RDHL Redhill Biopharma	-1.46%	+0.75%	-17.18%	-25.00%	-82.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERNA Ernexa Therapeutics	0.7643 of 5 stars	0.0	3.0	0.0	0.0	3.3	1.7	0.0
MBIO Mustang Bio	1.0542 of 5 stars	0.0	5.0	0.0	0.0	2.7	0.0	0.6
PHIO Phio Pharmaceuticals	2.7331 of 5 stars	3.5	2.0	0.0	0.0	2.7	2.5	0.6
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
MBIO Mustang Bio	0.00	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	3.00	Buy	$14.00	607.07% Upside
RDHL Redhill Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RDHL, PHIO, MBIO, and ERNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/25/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/5/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERNA Ernexa Therapeutics	$580K	18.25	N/A	N/A	$0.58 per share	2.38
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$0.40 per share	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.76 per share	N/A
RDHL Redhill Biopharma	$8.04M	0.38	N/A	N/A	($3.66) per share	-0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	0.00	∞	N/A	-7,652.75%	N/A	-682.08%	11/10/2025 (Estimated)
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-29.49%	11/6/2025 (Estimated)
PHIO Phio Pharmaceuticals	-$7.15M	-$3.25	0.00	0.53	N/A	N/A	-88.75%	-77.98%	11/13/2025 (Estimated)
RDHL Redhill Biopharma	-$8.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest RDHL, PHIO, MBIO, and ERNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PHIO Phio Pharmaceuticals	-$0.36	-$0.45	-$0.09	-$0.45	N/A	N/A
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A
8/8/2025	Q2 2025	MBIO Mustang Bio	N/A	-$0.19	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERNA Ernexa Therapeutics	N/A	1.81	1.81
MBIO Mustang Bio	N/A	1.30	1.30
PHIO Phio Pharmaceuticals	N/A	9.36	9.36
RDHL Redhill Biopharma	N/A	0.54	0.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERNA Ernexa Therapeutics	70.55%
MBIO Mustang Bio	9.95%
PHIO Phio Pharmaceuticals	57.31%
RDHL Redhill Biopharma	7.20%

Insider Ownership

Company	Insider Ownership
ERNA Ernexa Therapeutics	1.50%
MBIO Mustang Bio	0.21%
PHIO Phio Pharmaceuticals	0.89%
RDHL Redhill Biopharma	6.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERNA Ernexa Therapeutics	10	7.67 million	7.56 million	No Data
MBIO Mustang Bio	100	7.24 million	7.23 million	Not Optionable
PHIO Phio Pharmaceuticals	10	5.73 million	5.68 million	Not Optionable
RDHL Redhill Biopharma	210	2.30 million	2.14 million	No Data

RDHL, PHIO, MBIO, and ERNA Headlines

Recent News About These Companies

RedHill awarded $1.82M in legal costs and expenses in action against Kukbo

August 20, 2025 | msn.com

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

August 20, 2025 | prnewswire.com

RedHill Biopharma receives Talicia licensing payments totaling $1.1M

August 19, 2025 | msn.com

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

August 18, 2025 | prnewswire.com

RedHill Biopharma Granted Nasdaq Compliance Extension

August 14, 2025 | msn.com

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

July 21, 2025 | prnewswire.com

RDHL - Redhill Biopharma Ltd ADR Trailing Returns - Morningstar

July 18, 2025 | morningstar.comM

RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study

July 2, 2025 | msn.com

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

July 1, 2025 | prnewswire.com

RedHill Biopharma Ltd. (RDHL) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025 | prnewswire.com

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025 | prnewswire.com

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

April 28, 2025 | prnewswire.com

RedHill Biopharma receives non-compliance letter from Nasdaq

April 18, 2025 | markets.businessinsider.com

RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 18, 2025 | finanznachrichten.de

RedHill Biopharma announces publication in journal on Opaganib

April 17, 2025 | markets.businessinsider.com

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 17, 2025 | prnewswire.com

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

April 16, 2025 | prnewswire.com

RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

April 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL, PHIO, MBIO, and ERNA Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

$1.38 -0.01 (-0.72%)

Closing price 03:59 PM Eastern

Extended Trading

$1.48 +0.11 (+7.61%)

As of 06:56 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Mustang Bio NASDAQ:MBIO

$1.54 +0.02 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 0.00 (0.00%)

As of 07:52 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Phio Pharmaceuticals NASDAQ:PHIO

$1.98 -0.05 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.02 (+1.06%)

As of 07:49 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Redhill Biopharma NASDAQ:RDHL

$1.34 +0.01 (+0.75%)

Closing price 03:46 PM Eastern

Extended Trading

$1.35 +0.01 (+0.75%)

As of 05:30 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time